It is necessary to underline that although mutated ERBB2, PTPRT, PTPRD and AURKB predicted poor OS in univariate analysis they were excluded from the multivariate analysis because they were preferentially identified in patients with late stage (stage III-IV) and/or metastatic disease. The gene discussed is ERBB2; the disease is metastatic neoplasm.